Pharmaceutical Peak Body Slams "Broken" PBS System as Mounjaro Subsidy Stalls

Medicines Australia labels the PBS process "broken" as 450,000 diabetics miss out on subsidised Mounjaro due to stalled negotiations with Eli Lilly.

By: AXL Media

Published: Apr 28, 2026, 11:23 AM EDT

Source: ABC News

The Subsidy Stand-off and Impact on Diabetic Patients

A high-stakes negotiation between the Australian federal government and global pharmaceutical giant Eli Lilly has reached a definitive impasse, resulting in the withdrawal of the application to list tirzepatide (sold as Mounjaro) on the Pharmaceutical Benefits Scheme (PBS). Despite a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) that the drug be subsidized for adults with "inadequately controlled" type 2 diabetes, the manufacturer has pulled out of the process. Eli Lilly cited "unrealistic and unviable" pricing conditions proposed by the government, estimating that nearly half a million Australians will now miss out on significantly discounted access to the medication.

Industry Criticism of a Stagnant Regulatory Framework

Medicines Australia CEO Liz de Somer has sharply criticized the current regulatory environment, arguing that the Mounjaro stalemate is symptomatic of a "broken" system that fails to value medical innovation. The industry body notes that the median time for a new medicine to reach the PBS after regulatory approval is currently 22 months a delay they argue puts Australian patients at a disadvantage compared to other developed nations. While a major Health Technology Assessment (HTA) review was handed to the government in 2024 to address these bottlenecks, stakeholders argue that the slow pace of implementation is actively deterring global companies from bringing new therapies to the Australian market.

TRANSFORMATIVE ANALYSIS: The conflict highlights a growing friction between Australia’s rigid, cost-sensitive HTA process and the rapid evolution of metabolic medicines. As GLP-1 and GIP receptor agonists become blockbuster global commodities, Australia’s "single-payer" leverage is being tested by manufacturers who may find the domestic market less attractive if price ceilings remain significantly lower than international benchmarks.

Patient Hardship and the Reality of Medication Rationing